These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16142844)

  • 1. Introduction. D-hormones alfacalcidol and calcitriol for prevention and treatment of glucocorticoid/inflammation-induced osteoporosis.
    Sambrook PN; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():1-3. PubMed ID: 16142844
    [No Abstract]   [Full Text] [Related]  

  • 2. Alfacalcidol versus plain vitamin D in inflammation induced bone loss.
    Scharla SH; Schacht E; Lempert UG
    J Rheumatol Suppl; 2005 Sep; 76():26-32. PubMed ID: 16142848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD; Faber H; Fahramand P; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low creatinine clearance, glucocorticoid treatment, rheumatoid arthritis--different etiologies for low D-hormone syndrome and its associated increased risk for falls.
    Dukas LC; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():44-6. PubMed ID: 16142851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis, clinical feature and treatment of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis].
    Nakayama H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():499-503. PubMed ID: 18161156
    [No Abstract]   [Full Text] [Related]  

  • 6. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
    Kishimoto M; Oishi A; Motojima S
    N Engl J Med; 2006 Nov; 355(20):2156; author reply 2157. PubMed ID: 17108350
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
    Minisola S; Scillitani A; Romagnoli E
    N Engl J Med; 2006 Nov; 355(20):2156-7; author reply 2157. PubMed ID: 17120352
    [No Abstract]   [Full Text] [Related]  

  • 10. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.
    Yamada S; Takagi H; Tsuchiya H; Nakajima T; Ochiai H; Ichimura A; Iwata H; Toriyama T
    Yakugaku Zasshi; 2007 Sep; 127(9):1491-6. PubMed ID: 17827929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The D-hormone analog alfacalcidol: the pioneer beyond the horizon of osteoporosis treatment.
    Orimo H; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():4-10. PubMed ID: 16142845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
    Ringe JD; Schacht E
    Rheumatol Int; 2007 Dec; 28(2):103-11. PubMed ID: 17668216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol].
    Ziegler R
    Med Monatsschr Pharm; 2007 Mar; 30(3):122-3. PubMed ID: 17405496
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on glucocorticoid-induced osteoporosis.
    Maricic M
    Rheum Dis Clin North Am; 2011 Aug; 37(3):415-31, vi. PubMed ID: 22023900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-hormones for prevention of bone loss after organ transplant.
    Sambrook PN
    J Rheumatol Suppl; 2005 Sep; 76():41-3. PubMed ID: 16142850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for active vitamin D and analogs in the treatment of osteoporosis.
    Nishii Y
    J Cell Biochem; 2003 Feb; 88(2):381-6. PubMed ID: 12520540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
    Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
    Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Was it inappropriate to give patients with osteoporosis calcitriol instead of vitamin D?
    Vieth R
    J Am Geriatr Soc; 2008 Mar; 56(3):575-6; author reply 576-7. PubMed ID: 18315678
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.